Centessa Pharmaceuticals (CNTA) Retained Earnings (2020 - 2026)

Centessa Pharmaceuticals (CNTA) has 7 years of Retained Earnings data on file, last reported at $1.4 million in Q1 2026.

• Quarterly Retained Earnings fell 32.14% year-over-year to $1.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.4 million (down 32.14% YoY) and the FY2025 annual result came in at $2.7 million, up 100.27% from the prior year.
• Retained Earnings eased to $1.4 million in Q1 2026 per CNTA's latest filing, from $2.7 million in the prior quarter.
• Across five years, Retained Earnings topped out at $2.7 million in Q4 2025 and bottomed at -$1.1 billion in Q3 2025.
• The 5-year median for Retained Earnings is -$558.7 million (2022), against an average of -$470.2 million.
• The widest annual swing landed in 2022, when Retained Earnings tumbled 87579.65%; it then jumped 100.27% in 2025.
• Tracing CNTA's Retained Earnings over 5 years: stood at -$601.9 million in 2022, then declined by 25.1% to -$752.9 million in 2023, then sank by 31.31% to -$988.7 million in 2024, then jumped by 100.27% to $2.7 million in 2025, then tumbled by 48.12% to $1.4 million in 2026.
• Per Business Quant, the three latest CNTA Retained Earnings figures stand at $1.4 million (Q1 2026), $2.7 million (Q4 2025), and -$1.1 billion (Q3 2025).

Peer Comparison